Sengupta Sohini
Department of Social Medicine, University of North Carolina at Chapel Hill, MacNider Hall, CB#7240, Chapel Hill, NC 27599-7240, USA.
N C Med J. 2008 Jan-Feb;69(1):6-13.
Effective January 1, 2006 Medicare Part D became a new source of prescription drug coverage for people with HIV/AIDS in the United States. The implementation of Part D has affected access to antiretrovirals for people with HIV/AIDS. In North Carolina, access can be difficult because of the state's struggling safety net programs and the growing HIV-infected populations among Blacks and in poor rural counties. This analysis examines Medicare Part D antiretroviral coverage in 2007 for beneficiaries with HIV/AIDS in North Carolina, particularly those who did not qualify as dual eligibles or for a full low-income subsidy.
Data describing program coverage were obtained from the Web site www.medicare.gov and descriptive analyses were performed to assess changes in antiretroviral coverage in Part D prescription drug plans in North Carolina.
Most of the 26 antiretrovirals are covered in some way by 76 North Carolina prescription drug plans. There may be variability in coverage however associated with (a) antiretroviral classification within formularies; (b) drug premiums; (c) whether premiums can be waived; (d) annual deductibles; and (e) whether coverage is provided in the "doughnut hole."
The data may not reflect actual patterns of drug use and realized access to the drugs. The findings are limited to antiretroviral coverage in North Carolina's Part D offerings but could be generalized to other states with similar prescription drug plan costs and coverage.
These concerns continue to pose significant challenges to accessing antiretrovirals for Part D beneficiaries with HIV/AIDS in North Carolina. Variability demonstrated within prescription drug plans will continue, and beneficiaries with HIV/AIDS who do not qualify as dual eligibles or for low-income subsidies will need to evaluate these issues when selecting a prescription drug plan in future enrollment periods.
自2006年1月1日起,美国医疗保险D部分成为艾滋病病毒/艾滋病患者新的处方药覆盖来源。D部分的实施影响了艾滋病病毒/艾滋病患者获得抗逆转录病毒药物的情况。在北卡罗来纳州,由于该州安全网项目举步维艰以及黑人和贫困农村县中感染艾滋病病毒的人口不断增加,获取药物可能会很困难。本分析研究了2007年北卡罗来纳州艾滋病病毒/艾滋病受益人医疗保险D部分的抗逆转录病毒药物覆盖情况,特别是那些不符合双重资格或全额低收入补贴资格的受益人。
从网站www.medicare.gov获取描述项目覆盖情况的数据,并进行描述性分析,以评估北卡罗来纳州D部分处方药计划中抗逆转录病毒药物覆盖情况的变化。
北卡罗来纳州的76个处方药计划以某种方式覆盖了26种抗逆转录病毒药物中的大多数。然而,覆盖情况可能存在差异,这与以下因素有关:(a)处方集内的抗逆转录病毒药物分类;(b)药物保费;(c)保费是否可以豁免;(d)年度免赔额;以及(e)“甜甜圈洞”中是否提供覆盖。
这些数据可能无法反映实际的用药模式和实际获得药物的情况。研究结果仅限于北卡罗来纳州D部分提供的抗逆转录病毒药物覆盖情况,但可能适用于处方药计划成本和覆盖情况类似的其他州。
这些问题继续给北卡罗来纳州有艾滋病病毒/艾滋病的D部分受益人获取抗逆转录病毒药物带来重大挑战。处方药计划中显示的差异将继续存在,不符合双重资格或低收入补贴资格的艾滋病病毒/艾滋病受益人在未来注册期选择处方药计划时需要评估这些问题。